Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Relapsed/refractory, pathologically confirmed EBV+ lymphoid malignancy or lymphoproliferative disease~* Absence of available therapy with reasonable likelihood of cure or significant clinical benefit~* Adequate hematologic, hepatic and renal function as defined by laboratory assessment~Key Exclusion Criteria:~* Known primary CNS lymphoma~* Known CNS metastases or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks~* Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy~* Refractory graft versus host disease (GvHD) not responding to treatment~* Known active hepatitis B virus infection~* Circulating hepatitis C virus on qPCR~* Known history of HHV-6 chromosomal integration~* Known history of HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b Dose Escalation (Type: EXPERIMENTAL): VRx-3996 (cohort 1) and valganciclovir~VRx-3996 (cohort 2) and valganciclovir~VRx-3996 (cohort 3) and valganciclovir~VRx-3996 (cohort 4) and valganciclovir~VRx-3996 (cohort 5) and valganciclovir
- Phase 2 Dose Expansion (Type: EXPERIMENTAL): VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
- PK Cohort (Type: EXPERIMENTAL): Assessment of VRx-3996 tablet and valganciclovir PK parameters at the RP2D

Based on this trial design, predict the completion outcome and termination type (if applicable).